中文摘要：

目的 探讨血清肿瘤标志物糖类抗原125（CA125）在原发性胃弥漫大B细胞淋巴瘤（PG-DLBCL）中的临床意义。方法 回顾性分析2009年1月~2015年12月武汉大学人民医院54例初诊PG-DLBCL患者的临床资料,按照血清CA125水平进行分组：正常组（CA125≤35 U/m L）和升高组（CA125〉35 U/m L）。分析CA125水平与性别、B症状、临床分期、国际预后指标（IPI）及近期疗效的关系。结果 54例患者中,正常组34例,升高组20例。两组的性别分布比较,差异无统计学意义（P〉0.05）;两组B症状占比、临床分期、IPI比较,差异均有统计学意义（P〈0.05或P〈0.01）。结论 不同血清CA125水平的PG-DLBCL患者,其B症状、IPI指数、临床分期不同,而性别无明显差异。

英文摘要：

Objective To investigate the clinical significance of serum tumor markers carbohydrate antigen CAl25 in primary gastric diffuse large B-cell lymphoma （PG-DLBCL）. Methods Clinical data of 54 patients with PG-DLBCI, from January 2009 to December 2015 in the Renmin Hospital of Wuhan University were retrospectively analyzed, and they were divided into normal group （CA125 ≤35 U/ml,） and elevated group （CA125 〉 35 U/mL） according to the level of serum CA125. The relationship between serum CA125 and gender, B symptoms, clinical stage, international prognostic index （IPI）, short-term effect were analyzed. Results 34 cases were found in the normal group, and 20 cases were found in the elevated group. There was no significantly differeneein gender distribution of the two groups （P 〉 0.05）; but there were significantly differences in B symptoms, clinical stage, IPI of the two groups （P 〈 0.05 or P 〈 0.01）. Conclusion PG-DLBCL of differentserum CA125 had different B symptoms, clinical stage, IPI index and there was no significant difference in gender.